お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
973548

生体工学による代用皮膚の世界市場 (2020-2030年):市場予測 (製品・用途・エンドユーザー・地域別)・競合環境・法規制シナリオ

Global Bioengineered Skin Substitutes Market: Focus on Product Type, Application, End User, 4 Regional Data, 12 Countries' Data, Competitive Landscape, Regulatory Scenario, Analysis and Forecast, 2020-2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 210 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.75円
生体工学による代用皮膚の世界市場 (2020-2030年):市場予測 (製品・用途・エンドユーザー・地域別)・競合環境・法規制シナリオ
出版日: 2020年12月01日
発行: BIS Research Inc.
ページ情報: 英文 210 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の生体工学による代用皮膚の市場規模は2030年には43億3000万米ドルの規模に成長すると予測されています。組織工学分野における革新、創傷生物学における技術的進歩、慢性創傷や火傷の発生率の増加、政府による資金投入などの要因が同市場の成長を推進しています。

当レポートでは、世界の生体工学による代用皮膚の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、関連法規制、上市済み製品、市場規模の推移・予測、製品・用途・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 製品の定義

第2章 調査範囲

第3章 調査手法

第4章 市場概要

  • 代用皮膚:イントロダクション
  • 生体工学による代用皮膚
  • 組織工学の経緯・タイムライン
  • 代用皮膚の分類・種類
  • 上市済み製品
  • 今後の動向・展開
  • 対象市場の規模・成長の可能性

第5章 市場力学

  • 概要
  • 影響分析
  • 市場成長推進因子
  • 市場成長抑制因子
  • 市場機会

第6章 産業考察

  • 産業の進化
  • 法規制の枠組み
  • 創傷管理コスト
  • 創傷ケア製品のサプライチェーン

第7章 競合情勢

  • 概要
  • 主な展開・戦略
  • 市場シェア分析
  • 成長シェア分析(機会マッピング)

第8章 市場分析・予測:製品別

  • 概要
  • 同種異系
  • 自家
  • 異種遺伝子
  • 無細胞
  • その他

第9章 市場分析・予測:用途別

  • 概要
  • 慢性創傷
    • 静脈性下肢潰瘍
    • 糖尿病性足潰瘍(DFU)
    • 褥瘡(PU)
    • その他
  • 急性創傷
    • 外科的・外傷性創傷
    • 火傷

第10章 市場分析・予測:エンドユーザー別

  • 概要
  • 病院
  • 専門クリニック
  • 創傷ケアセンター
  • その他

第11章 市場分析・予測:地域・主要国別

  • 概要
  • 北米
    • 概要
    • 米国
    • カナダ
  • 欧州
    • 概要
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 概要
    • 中国
    • 日本
    • オーストラリア
    • 韓国
    • インド
    • その他
  • その他の地域

第12章 企業プロファイル

  • Boston Scientific Corporation
  • Smith & Nephew plc
  • AbbVie Inc.
  • Stryker Corporation
  • Anika Therapeutics, Inc.
  • Zimmer Biomet Holdings, Inc.
  • Vericel Corporation
  • Integra LifeSciences Corporation
  • Aroa Biosurgery Limited
  • Organogenesis Inc.
  • Molnlycke Health Care AB
  • AlloSource
  • Cook Biotech Incorporated
  • Promethean LifeSciences, Inc.
  • ACell, Inc.
図表

List of Tables

  • Table 1: Leading Segments of the Global Bioengineered Skin Substitutes Market (by Revenue), 2019 and 2030
  • Table 4.1: Examples of Key Companies Offering Bioengineered Skin Substitutes
  • Table 5.1: Impact Analysis of Market Drivers
  • Table 5.2: Impact Analysis of Market Restraints
  • Table 5.3: Global Statistics of Diabetes and Diabetic Foot Ulcers
  • Table 5.4: Global Prevalence of Pressure Ulcer and Venous Leg Ulcer, 2018
  • Table 5.5: Examples of Acellular Skin Substitutes Offered by Key Companies
  • Table 6.1: Human-Derived Products Regulated Solely Under 21 CFR 1271 (HCT/Ps)
  • Table 6.2: Human and Human/Animal-Derived Products Regulated Through the Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Process
  • Table 6.3: Animal-Derived Products Regulated Under the 510(K) Process
  • Table 6.4: Biosynthetic Products Regulated Under the 510(K) Process
  • Table 7.1: M&A Activities (January 2017 and September 2020)
  • Table 7.2: Partnership and Alliances (January 2017 and September 2020)
  • Table 7.3: Business Expansions (January 2017 and September 2020)
  • Table 7.4: Other Key Developments (January 2017 and September 2020)
  • Table 8.1: Allogenic Products Offered by Key Companies
  • Table 8.2: Autologous Products Offered by Key Companies
  • Table 8.3: Xenogeneic Products Offered by Key Companies
  • Table 8.4: Acellular Products Offered by Key Companies
  • Table 9.1: Major Wound Types
  • Table 9.2: Global Venous Leg Ulcer Statistics
  • Table 9.3: Global Diabetic Foot Ulcer Statistics
  • Table 9.4: Global Pressure Ulcer Statistics

List of Figures

  • Figure 1: Global Bioengineered Skin Substitutes Market
  • Figure 2: Impact of Market Drivers and Market Restraints
  • Figure 3: Competitive Landscape (Key Developments: January 2017-September 2020)
  • Figure 4: Global Bioengineered Skin Substitutes Market Share (by Product), 2019 and 2030
  • Figure 5: Global Bioengineered Skin Substitutes Market Share (by Application), 2019 and 2030
  • Figure 6: Global Bioengineered Skin Substitutes Market Share (by End User), 2019 and 2030
  • Figure 7: Global Bioengineered Skin Substitutes Market Share (by Region), 2019 and 2030
  • Figure 2.1: Global Bioengineered Skin Substitutes Market Segmentation
  • Figure 3.1: Global Bioengineered Skin Substitutes Market Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
  • Figure 3.4: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 4.1: Common Characteristics of Ideal Skin Substitutes
  • Figure 4.2: Timeline of Skin Tissue Engineering in Burn Surgery
  • Figure 4.3: Different Classification of Skin Substitutes
  • Figure 4.4: Future Trends and Developments in Bioengineering/Tissue Engineering Market
  • Figure 4.5: Global Bioengineered Skin Substitutes Market (by Value)
  • Figure 5.1: Market Dynamics
  • Figure 5.2: Major Limitations of Skin Substitutes
  • Figure 6.1: Industry Trends in Advanced Wound Care Market
  • Figure 6.1: Cost Breakup, Wound Management Life Cycle
  • Figure 7.1: Competitive Landscape (January 2017- April 2020)
  • Figure 7.2: Share of Key Developments and Strategies, January 2017-June 2020
  • Figure 7.3: Market Share Analysis of Global Bioengineered Skin Substitutes Market, 2019
  • Figure 7.4: Growth Share Matrix for Global Bioengineered Skin Substitutes Market (by Product), 2019-2030
  • Figure 7.5: Growth Share Matrix for Global Bioengineered Skin Substitutes Market (by Application), 2019-2030
  • Figure 8.1: Global Bioengineered Skin Substitutes Market Segmentation (by Product)
  • Figure 8.2: Global Bioengineered Skin Substitutes Market (by Product), 2019-2030
  • Figure 8.3: Global Bioengineered Skin Substitutes Market (Allogenic Products), 2019-2030
  • Figure 8.4: Global Bioengineered Skin Substitutes Market (Autologous Products), 2019-2030
  • Figure 8.5: Global Bioengineered Skin Substitutes Market (Xenogeneic Products), 2019-2030
  • Figure 8.6: Global Bioengineered Skin Substitutes Market (Acellular Products), 2019-2030
  • Figure 8.7: Global Bioengineered Skin Substitutes Market (Other Products), 2019-2030
  • Figure 9.1: Global Bioengineered Skin Substitutes Market Segmentation (by Application)
  • Figure 9.2: Global Bioengineered Skin Substitutes Market (by Application), 2019-2030
  • Figure 9.3: Global Bioengineered Skin Substitutes Market (by Chronic Wound), 2019-2030
  • Figure 9.4: Global Bioengineered Skin Substitutes Market (by Chronic Wound Disease Type), 2019-2030
  • Figure 9.5: Global Bioengineered Skin Substitutes Market (Venous Leg Ulcers), 2019-2030
  • Figure 9.6: Global Bioengineered Skin Substitutes Market (Diabetic Foot Ulcers), 2019-2030
  • Figure 9.7: Global Bioengineered Skin Substitutes Market (Pressure Ulcers), 2019-2030
  • Figure 9.8: Global Bioengineered Skin Substitutes Market (Other Chronic Wounds), 2019-2030
  • Figure 9.9: Global Bioengineered Skin Substitutes Market (by Acute Wound), 2019-2030
  • Figure 9.10: Global Bioengineered Skin Substitutes Market (by Acute Wound), 2019-2030
  • Figure 9.11: Global Bioengineered Skin Substitutes Market ( Surgical and Traumatic Wounds), 2019-2030
  • Figure 9.12: Global Bioengineered Skin Substitutes Market (Burn Injury), 2019-2030
  • Figure 10.1: Global Bioengineered Skin Substitutes Market Segmentation (by End User)
  • Figure 10.2: Global Bioengineered Skin Substitutes Market (by End User), 2019-2030
  • Figure 10.3: Global Bioengineered Skin Substitutes Market (Hospitals), 2019-2030
  • Figure 10.4: Global Bioengineered Skin Substitutes Market (Specialty Clinic), 2019-2030
  • Figure 10.5: Global Bioengineered Skin Substitutes Market (Wound Care Centers), 2019-2030
  • Figure 10.6: Global Bioengineered Skin Substitutes Market (Others), 2019-2030
  • Figure 11.1: Global Bioengineered Skin Substitutes Market (by Region), 2019 and 2030
  • Figure 11.2: Global Bioengineered Skin Substitutes Market (by Region), 2019-2030
  • Figure 11.3: North America: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.4: North America: Market Dynamics
  • Figure 11.5: North America Bioengineered Skin Substitutes Market Share (by Country), 2019-2030
  • Figure 11.6: U.S. Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.7: Canada Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.8: Europe Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.9: Europe: Market Dynamics
  • Figure 11.10: Europe: Bioengineered Skin Substitutes Market Share (by Country), 2019-2030
  • Figure 11.11: Germany Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.12: U.K. Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.13: France: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.14: Italy: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.15: Spain: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.16: Rest-of-Europe: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.17: Asia-Pacific: Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.18: Asia-Pacific: Market Dynamics
  • Figure 11.19: Asia-Pacific: Bioengineered Skin Substitutes Market Share (by Country), 2019-2030
  • Figure 11.20: China Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.21: Japan Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.22: Australia Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.23: South Korea Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.24: India Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.25: Rest-of-Asia-Pacific Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 11.26: Rest-of-the-World Bioengineered Skin Substitutes Market, 2019-2030
  • Figure 12.1: Shares of Key Company Profiles
  • Figure 12.2: Boston Scientific Corporation: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.3: Boston Scientific Corporation: Overall Financials, 2017-2019
  • Figure 12.4: Boston Scientific Corporation: Revenue (by Segment), 2017-2019
  • Figure 12.5: Boston Scientific Corporation: Revenue (by Region), 2017-2019
  • Figure 12.6: Boston Scientific Corporation: R&D Expenditure, 2017-2019
  • Figure 12.7: Boston Scientific Corporation: SWOT Analysis
  • Figure 12.8: Smith & Nephew plc: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.9: Smith & Nephew plc: Overall Financials, 2017-2019
  • Figure 12.10: Smith & Nephew plc: Revenue (by Segment), 2017-2019
  • Figure 12.11: Smith & Nephew plc: Revenue (by Region), 2017-2019
  • Figure 12.12: Smith & Nephew plc: R&D Expenditure, 2017-2019
  • Figure 12.13: Smith & Nephew plc: SWOT Analysis
  • Figure 12.14: AbbVie Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.15: AbbVie Inc.: Overall Financials, 2017-2019
  • Figure 12.16: AbbVie Inc.Revenue (by Region), 2017-2019
  • Figure 12.17: AbbVie Inc.: R&D Expenditure, 2017-2019
  • Figure 12.18: AbbVie Inc.: SWOT Analysis
  • Figure 12.19: Stryker Corporation: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.20: Stryker Corporation: Overall Financials, 2017-2019
  • Figure 12.21: Stryker Corporation: Revenue (by Segment), 2017-2019
  • Figure 12.22: Stryker Corporation: Revenue (by Region), 2017-2019
  • Figure 12.23: Stryker Corporation: SWOT Analysis
  • Figure 12.24: Anika Therapeutics, Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.25: Anika Therapeutics, Inc.: Overall Financials, 2017-2019
  • Figure 12.26: Anika Therapeutics, Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.27: Anika Therapeutics, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.28: Anika Therapeutics, Inc.: R&D Expenditure, 2017-2019

Figure12.29: Anika Therapeutics, Inc.: SWOT Analysis

  • Figure 12.30: Zimmer Biomet Holdings, Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.31: Zimmer Biomet Holdings, Inc.: Overall Financials, 2017-2019
  • Figure 12.32: Zimmer Biomet Holdings, Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.33: Zimmer Biomet Holdings, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.34: Zimmer Biomet Holdings, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.35: Zimmer Biomet Holdings, Inc.: SWOT Analysis
  • Figure 12.36: Vericel Corporation: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12 37: Vericel Corporation: Overall Financials, 2017-2019
  • Figure 12.38: Vericel Corporation: Revenue (by Segment), 2017-2019
  • Figure 12.39: Vericel Corporation: R&D Expenditure, 2017-2019
  • Figure 12.40: Vericel Corporation: SWOT Analysis
  • Figure 12.41: Integra LifeSciences Corporation: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.42: Integra LifeSciences Corporation: Overall Financials, 2017-2019
  • Figure 12.43: Integra LifeSciences Corporation: Revenue (by Segment), 2017-2019
  • Figure 12.44: Integra LifeSciences Corporation: Revenue (by Region), 2017-2019
  • Figure 12.45: Integra LifeSciences Corporation: R&D Expenditure, 2017-2019
  • Figure 12.46: Integra LifeSciences Corporation: SWOT Analysis
  • Figure 12.47: Aroa Biosurgery Limited: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.48: Aroa Biosurgery Limited: SWOT Analysis
  • Figure 12.49: Organogenesis Holdings Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.50: Organogenesis Holdings Inc.: Overall Financials, 2017-2019
  • Figure 12.51: Organogenesis Holdings Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.52: Organogenesis Holdings Inc.: R&D Expenditure, 2017-2019
  • Figure 12.53: Organogenesis Holdings Inc.: SWOT Analysis
  • Figure 12.54: Molnlycke Health Care AB: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.55: Molnlycke Health Care AB: SWOT Analysis
  • Figure 12.56: AlloSource: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.57: AlloSource: SWOT Analysis
  • Figure 12.58: Cook Biotech Incorporated: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.59: Cook Biotech Incorporated: SWOT Analysis
  • Figure 12.60: Promethean LifeSciences, Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.61: Promethean LifeSciences, Inc.: SWOT Analysis
  • Figure 12.62: ACell, Inc.: Product Portfolio for Global Bioengineered Skin Substitutes Market
  • Figure 12.63: ACell, Inc.: SWOT Analysis
目次
Product Code: BHL1012SA

"Global Bioengineered Skin Substitutes Market to Reach $4.33 Billion by 2030."

Market Report Coverage - Bioengineered Skin Substitutes

Market Segmentation

  • By Product: Allogenic, Autologous, Xenogeneic, Acellular, and Others
  • By Application: Chronic Wounds and Acute Wounds
  • By End User: Hospitals, Specialty Clinics, Wound Care Centers, and Others

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
  • Asia-Pacific - China, Australia, Japan, India, South Korea, and Rest-of-Asia-Pacific
  • Rest-of-the-World

Growth Drivers

  • Increasing Prevalence of Diabetes and Diabetic Foot Ulcers
  • Rising Cases of Chronic Wounds and Burn Injuries
  • Increasing Funds/Aids by the Government for Research Purposes
  • Growing Prominence of Regenerative Medicine and Tissue Engineering Products
  • Increasing Obesity

Market Challenges

  • Biocompatibility Issues and Stringent Regulations
  • Limitations of Skin Substitutes
  • Expensive Treatment

Market Opportunities

  • Patient Awareness and Improved Lifestyle in Emerging Economics
  • Advancing Inclination Toward Acellular Skin Substitutes

Key Companies Profiled

Anika Therapeutics, Inc., AbbVie, Inc., Smith & Nephew plc, Integra LifeSciences Corporation, Boston Scientific Corporation, Organogenesis, Inc., Molnlycke Health Care AB, Vericel Corporation, Stryker Corporation, Zimmer Biomet, and Aroa Biosurgery, Cook Biotech Incorporated, Promethean LifeSciences, Inc., XCELLentis NV, and AlloSource

Key Questions Answered in this Report:

  • What is the importance of bioengineered skin substitutes, and what is their origin? What are the different bioengineered skin substitutes products available in the market, and what are their benefits?
  • What are the major technological advancements witnessed by the global bioengineered skin substitutes market since 2015, and what is the future scope of the market? What are the current key trends of the global bioengineered skin substitutes market, and how is the market evolving?
  • What was the market size of the global bioengineered skin substitutes market in 2019, and what is the market size anticipated to be in 2030? What is the expected growth rate of the global bioengineered skin substitutes market during the period between 2020 and 2030?
  • What is the market scenario and growth potential of different regions of the world, including North America, Europe, Asia-Pacific, and Rest-of-the-World?
  • What are the major drivers, challenges, and opportunities of the global bioengineered skin substitutes market?
  • What are the major key players of the global bioengineered skin substitutes market? How much market share did each of these players occupy in the market in 2019? Which companies are anticipated to be highly disruptive in the future, and why?
  • What is the regulatory scenario of the global bioengineered skin substitutes market? What are the initiatives implemented by different governmental bodies and guidelines put forward by them to regulate the commercialization of bioengineered skin substitutes products?
  • What is the supply chain associated with wound care, and what is the cost associated with it?
  • What are the key developmental strategies implemented by the key players of the global bioengineered skin substitutes market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
  • What is the current revenue contribution of the global bioengineered skin substitutes market (by product type), and how is it expected to evolve in the forecast period?
  • What is the current revenue contribution of the global bioengineered skin substitutes market (by application type), and how is it expected to evolve in the forecast period?
  • What is the current revenue contribution of the global bioengineered skin substitutes market (by end user), and how is it expected to evolve in the forecast period?
  • Which region is expected to contribute the highest sales in the global bioengineered skin substitutes market during the period between 2019 and 2030? What are the leading countries of different regions that contribute significantly toward the growth of the global bioengineered skin substitutes market?

Market Overview

Technological advancements in wound biologics coupled with innovations in the field of tissue engineering have led to the development of advanced wound healing options and strategies, including bioengineered skin substitutes. These products are being designed to treat a wide range of acute and chronic wounds that pose a serious healthcare threat globally. According to a study published in the International Society for Pharmacoeconomics and Outcomes Research's Value in Health Journal (January 2018), the economic costs associated with chronic wound management in the U.S. is pegged between $28.1 to $31.7 billion for 8.2 million affected patients. Hence, increasing incidence of chronic wounds, as well as rising cases of burns injuries, are actively promoting the growth of the global bioengineered skin substitutes market. Further, the factors contributing to the huge demand for skin substitutes are their emerging applications, superior property, and huge investment by government and federal agencies.

BIS healthcare experts have found the global bioengineered skin substitutes market as one of the markets with high attractiveness from the investors, promoting huge investment driving technological innovations. The purpose of this study is to gain a holistic view of the bioengineered skin substitutes market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the products, applications, and end users associated with the global bioengineered skin substitutes market across different regions. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global bioengineered skin substitutes market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

Within the research report, the market has been segmented into 'products', 'applications', 'end-user', and 'regions'. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The bioengineered skin substitutes market is currently at a blooming phase, with the presence of various juggernauts such as AbbVie, Inc., Integra LifeSciences Corporation, Smith & Nephew plc, and Stryker Corporation, and other medium and small-medium enterprises that are offering a wide range of bioengineered skin substitutes products in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.

Table of Contents

Executive Summary

1. Product Definition

  • 1.1. Inclusion and Exclusion

2. Scope of the Work

  • 2.1. Overview: Report Scope
  • 2.2. Segmentation of the Global Bioengineered Skin Substitutes Market
  • 2.3. Assumptions and Limitations
  • 2.4. Key Questions Answered in the Report
  • 2.5. Base Year and Forecast Period

3. Research Methodology

  • 3.1. Overview: Report Methodology
  • 3.2. Primary Data Sources
  • 3.3. Secondary Data Sources
  • 3.4. Market Estimation Model
  • 3.5. Criteria for Company Profiling

4. Market Overview

  • 4.1. Introduction to Skin Substitutes
  • 4.2. Bioengineered Skin Substitutes
  • 4.3. History and Timeline of Tissue Engineering
  • 4.4. Classification and Types of Skin Substitutes
  • 4.5. Key Products Commercially Available in the Market
  • 4.6. Future Trends and Developments
  • 4.7. Addressable Market Size and Growth Potential, $Million, 2019-2030

5. Market Dynamics

  • 5.1. Overview
  • 5.2. Impact Analysis
  • 5.3. Market Drivers
    • 5.3.1. Increasing Prevalence of Diabetes and Diabetic Foot Ulcers
    • 5.3.2. Rising Cases of Chronic Wounds and Burn Injuries
    • 5.3.3. Increasing Funds/Aids by Governments for Research Purposes
    • 5.3.4. Growing Prominence of Regenerative Medicines and Tissue-Engineering Products
    • 5.3.5. Increasing Obesity
  • 5.4. Market Restraints
    • 5.4.1. Biocompatibility Issues and Stringent Regulations
    • 5.4.2. Limitations of Skin Substitutes
    • 5.4.3. Expensive Treatment
  • 5.5. Market Opportunities
    • 5.5.1. Patient Awareness and Improved Lifestyle in Emerging Economies
    • 5.5.2. Advancing Inclination Toward Acellular Skin Substitutes

6. Industry Insights

  • 6.1. Industry Evolution
  • 6.2. Regulatory Framework Monitoring Skin Substitutes
    • 6.2.1. Human-Derived Products Regulated Solely Under 21 CFR 1271 (HCT/Ps)
    • 6.2.2. Human and Human/Animal-Derived Products Regulated Through the Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Process
    • 6.2.3. Animal-Derived Products Regulated Under the 510(K) Process
    • 6.2.4. Biosynthetic Products Regulated Under the 510(K) Process
  • 6.3. Wound Management Cost
  • 6.4. Supply Chain of Wound Care Products

7. Competitive Landscape

  • 7.1. Overview
  • 7.2. Key Developments and Strategies
    • 7.2.1. M & A Activities
    • 7.2.2. Partnerships and Alliances
    • 7.2.3. Business Expansion
    • 7.2.4. Others
  • 7.3. Market Share Analysis
  • 7.4. Growth Share Analysis (Opportunity Mapping)
    • 7.4.1. By Product
    • 7.4.2. By Application

8. Global Bioengineered Skin Substitutes Market (by Product)

  • 8.1. Overview
  • 8.2. Allogenic
  • 8.3. Autologous
  • 8.4. Xenogeneic
  • 8.5. Acellular
  • 8.6. Other Products

9. Global Bioengineered Skin Substitutes Market (by Application)

  • 9.1. Overview
  • 9.2. Chronic Wounds
    • 9.2.1. Venous Leg Ulcers
    • 9.2.2. Diabetic Foot Ulcers (DFU)
    • 9.2.3. Pressure Ulcers (PUs)
    • 9.2.4. Other Chronic Wounds
  • 9.3. Acute Wounds
    • 9.3.1. Surgical and Traumatic Wounds
    • 9.3.2. Burn Injuries

10. Global Bioengineered Skin Substitutes Market (by End User)

  • 10.1. Overview
  • 10.2. Hospitals
  • 10.3. Specialty Clinics
  • 10.4. Wound Care Centers
  • 10.5. Others

11. Global Bioengineered Skin Substitutes Market (by Region)

  • 11.1. Overview
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. U.S.
    • 11.2.3. Canada
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Germany
    • 11.3.3. U.K.
    • 11.3.4. France
    • 11.3.5. Italy
    • 11.3.6. Spain
    • 11.3.7. Rest-of-Europe
  • 11.4. Asia-Pacific
    • 11.4.1. Overview
    • 11.4.2. China
    • 11.4.3. Japan
    • 11.4.4. Australia
    • 11.4.5. South Korea
    • 11.4.6. India
    • 11.4.7. Rest-of-Asia-Pacific
  • 11.5. Rest-of-the-Word

12. Company Profiles

  • 12.1. Overview
  • 12.2. Boston Scientific Corporation
    • 12.2.1. Company Overview
    • 12.2.2. Role of Boston Scientific Corporation in the Global Bioengineered Skin Substitutes Market
    • 12.2.3. Financials
    • 12.2.4. Key Insights About Financial Health of the Company
    • 12.2.5. SWOT Analysis
  • 12.3. Smith & Nephew plc
    • 12.3.1. Company Overview
    • 12.3.2. Role of Smith & Nephew plc in the Global Bioengineered Skin Substitutes Market
    • 12.3.3. Financials
    • 12.3.4. Key Insights About Financial Health of the Company
    • 12.3.5. SWOT Analysis
  • 12.4. AbbVie Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Role of AbbVie Inc. in the Global Bioengineered Skin Substitutes Market
    • 12.4.3. Financials
    • 12.4.4. Key Insights About Financial Health of the Company
    • 12.4.5. SWOT Analysis
  • 12.5. Stryker Corporation
    • 12.5.1. Company Overview
    • 12.5.2. Role of Stryker Corporation in the Global Bioengineered Skin Substitutes Market
    • 12.5.3. Financials
    • 12.5.4. SWOT Analysis
  • 12.6. Anika Therapeutics, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Role of Anika Therapeutics, Inc. in the Global Bioengineered Skin Substitutes Market
    • 12.6.3. Financials
    • 12.6.4. Key Insights About Financial Health of the Company
    • 12.6.5. SWOT Analysis
  • 12.7. Zimmer Biomet Holdings, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Role of Zimmer Biomet Holdings, Inc. in the Global Bioengineered Skin Substitutes Market
    • 12.7.3. Financials
    • 12.7.4. Key Insights About Financial Health of the Company
    • 12.7.5. SWOT Analysis
  • 12.8. Vericel Corporation
    • 12.8.1. Company Overview
    • 12.8.2. Role of Vericel Corporation in Global Bioengineered Skin Substitutes Market
    • 12.8.3. Financials
    • 12.8.4. Key Insights About Financial Health of the Company
    • 12.8.5. SWOT Analysis
  • 12.9. Integra LifeSciences Corporation
    • 12.9.1. Company Overview
    • 12.9.2. Role of Integra LifeSciences Corporation in the Global Bioengineered Skin Substitutes Market
    • 12.9.3. Financials
    • 12.9.4. Key Insights About Financial Health of the Company
    • 12.9.5. SWOT Analysis
  • 12.1. Aroa Biosurgery Limited
    • 12.10.1. Company Overview
    • 12.10.2. Role of Aroa Biosurgery Limited in the Global Bioengineered Skin Substitutes Market
    • 12.10.3. SWOT Analysis
  • 12.11. Organogenesis Inc.
    • 12.11.1. Company Overview
    • 12.11.2. Role of Organogenesis Holdings Inc. in the Global Bioengineered Skin Substitutes Market
    • 12.11.3. Financials
    • 12.11.4. Key Insights About Financial Health of the Company
    • 12.11.5. SWOT Analysis
  • 12.12. Molnlycke Health Care AB
    • 12.12.1. Company Overview
    • 12.12.2. Role of Molnlycke Health Care AB in the Global Bioengineered Skin Substitutes Market
    • 12.12.3. SWOT Analysis
  • 12.13. AlloSource
    • 12.13.1. Company Overview
    • 12.13.2. Role of AlloSource in the Bioengineered Skin Substitutes Market
    • 12.13.3. SWOT Analysis
  • 12.14. Cook Biotech Incorporated
    • 12.14.1. Company Overview
    • 12.14.2. Role of Cook Biotech Incorporated in the Bioengineered Skin Substitutes Market
    • 12.14.3. SWOT Analysis
  • 12.15. Promethean LifeSciences, Inc.
    • 12.15.1. Company Overview
    • 12.15.2. Role of Promethean LifeSciences, Inc. in the Bioengineered Skin Substitutes Market
    • 12.15.3. SWOT Analysis
  • 12.16. ACell, Inc.
    • 12.16.1. Company Overview
    • 12.16.2. Role of ACell, Inc. in the Bioengineered Skin Substitutes Market
    • 12.16.3. SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.